The spectrum of levodopa-induced dyskinesias

Annals of Neurology

Volumn 47, Issue 4 SUPPL. 1, 2000, Pages

  Fahn, Stanley ^a,b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIDOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; SELEGILINE; TOCOPHEROL;

CHOREA; CONFERENCE PAPER; DRUG INDUCED DISEASE; DYSKINESIA; DYSTONIA; HUMAN; MYOCLONUS; ON OFF PHENOMENON; PARKINSON DISEASE; PRIORITY JOURNAL;

DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 0034109726     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - clinical aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982: 96-122
2. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, eds. Movement disorders. London: Butterworth Scientific, 1982:123-145
3. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276: 374-379
4. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280: 337-345
5. Yahr MD, Duvoisin RC, Schear MJ, et al. Treatment of parkinsonism with levodopa. Arch Neurol 1969;21:343-354
6. McDowell F, Lee JE, Swift T, et al. Treatment of Parkinson's syndrome with dihydroxyphenylalanine (levodopa). Ann Intern Med 1970;72:29-35
7. Schwarz GA, Fahn S. Newer medical treatments in parkinsonism. Med Clin North Am 1970;54:773-785
8. Calne DB, Reid JL, Vakil SD, Pallis C. Problems with L-dopa therapy. Clin Med 1971;78:21-23
9. Duvoisin RC. Hyperkinetic reactions with L-DOPA. In: Yahr MD, ed. Current concepts in the treatment of parkinsonism. New York: Raven Press, 1974:203-210
10. Klawans HL, Goetz C, Bergen D. Levodopa-induced myoclonus. Arch Neurol 1975;32:331-334
11. Sweet RD, McDowell FH. The 'on-off' response to chronic L-DOPA treatment of parkinsonism. Adv Neurol 1974;5:331-338
12. Duvoisin RC. Variations in the 'on-off' phenomenon. Adv Neurol 1974;5:339-340
13. Yahr MD. Variations in the 'on-off' effect. Adv Neurol 1974;5: 397-399
14. Fahn S. 'On-off' phenomenon with levodopa therapy in parkinsonism: clinical and pharmacologic correlations and the effect of intramuscular pyridoxine. Neurology 1974;24:431-441
15. Fahn S. Medical treatment of movement disorders. In: Davis FA, ed. Neurological reviews 1976. Minneapolis: American Academy of Neurology, 1976:72-106
16. Marsden CD, Parkes JD. 'On-off' effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;i: 292-295
17. Muentet MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ('I-D-I' and 'D-I-D') in response to L-dopa therapy of Parkinson's disease. Mayo Clin Proc 1977;52:163-174
18. Melamed E. Early-morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979;36: 308-310
19. Crystal HA, Dickson DW, Lizardi JE, et al. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990;40:1523-1528
20. Louis ED, Klatka LA, Liu Y, Fahn S. Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson's disease. Neurology 1997;48:376-380
21. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45
22. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226
23. Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991;41:622-629
24. Calne DB, Stern GM, Laurence DR, et al. L-Dopa in postencephalitic parkinsonism. Lancet 1969;1:744-746
25. Sacks OW, Kohl M, Schwartz W, Messeloff C. Side-effects of L-dopa in postencephalic parkinsonism. Lancet 1970;i:1006
26. Duvoisin RC, Lobo-Antunes J, Yahr MD. Response of patients with postencephalitic Parkinsonism to levodopa. J Neurol Neurosurg Psychiatry 1972;35:487-495
27. Langston JW, Ballard PA. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-cetrahydropyridine: implications for treatment and the pathophysiology of Parkinson's disease. Can J Neurosci 1984; 11:160-165
28. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980
29. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956
30. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91
31. Kostic V, Przedborski S, Flaster E, Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 1991;41:202-205
32. Blanchet PJ, Allard P, Gregoire L, et al. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci 1996;23:189-193
33. Wagner ML, Fedak MN, Sage JI, Mark MH. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci 1996;26:389-395
34. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:527-543
35. Sassin JF, Taub S, Weitzman ED. Hyperkinesia and changes in behavior produced in normal monkeys by L-dopa. Neurology 1972;22:1122-1125
36. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement disorders 3. Oxford: Butterworth-Heinemann, 1994: 262-281
37. Lhermitte F, Agid Y, Signoret JL. Onset and end-of-dose levodopa-induced dyskinesias. Arch Neurol 1978;35:261-262
38. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124
39. Ilson J, Fahn S, Cote L. Painful dystonic spasms in Parkinson's disease. Adv Neurol 1984;40:395-398
40. Bravi D, Mouradian MM, Roberts JW, et al. End-of-dose dystonia in Parkinson's disease. Neurology 1993;43:2130-2131
41. de Yebenes JG, Vazquez A, Martinez A, et al. Biochemical findings in symptomatic dystonias. Adv Neurol 1988;50:167-175
42. Pahwa R, Busenbark K, Huber SJ, et al. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 1993;43:677-681